Qlaris Bio Enrolls First Patient in Phase 1/2 Studies of QLS-101, an Investigational TherapyDesigned to Lower Episcleral Venous Pressure (EVP) in Patients with Glaucoma -Phase 1/2 Initiation Follows FDA Acceptance of Investigational New Drug (IND) Application- Wellesley, Mass., April 15, 2021 — Qlaris Bio, Inc., a biotechnology company targeting high unmet needs in debilitating ophthalmic […]
Archives for ryan